ESPE2022 Poster Category 1 Bone, Growth Plate and Mineral Metabolism (46 abstracts)
Background: Achondroplasia (ACH), caused by a pathogenic variant in the fibroblast growth factor receptor 3 gene (FGFR3), is characterized by severe growth failure and may be associated with multisystemic complications. The clinical phenotype is variable and relates to deformity of rhizomelic shortened legs, and myelon compression at cranial base and spine. Recent guidelines are published for diagnostic workflow, neurosurgical, orthopaedic and otorhinolaryngological interventions. Vosoritide, an analog of C-type natriuretic peptide, has been developed for the treatment of short stature in children with achondroplasia, and was approved by the EMA in August 2021 for ACH treatment. In a collaborative approach, we present epidemiological data characterizing the current practice of multidisciplinary treatment in Portugal, Austria, and Germany.
Patients: Medical history and clinical data were obtained routinely as standard of care from 575 children with ACH aged <17 years. Auxological data, safety of Vosoritide therapy and QoL data will be prospectively collected during routine visits. RESULTS: Since October 2021, Vosoritide had been started in 164 (29%) children: 80 aged 2-6y. (49%), 56 (34%) aged 7-11 y. and 28 (17%) aged >11y. At time of report in April 2022 all patients continued drug therapy. Related to the whole achondroplasia group 19% received a cranial decompression surgery and 8% limb lengthening.
Outlook: (1) To facilitate data collection, an achondroplasia-specific list of items has been inserted in the web-based registry CrescNet. (2) Prospective data acquisition by a multicenter approach aims to increase greater patient safety and longitudinal evaluation of treatment response.
15 Sep 2022 - 17 Sep 2022